H.C. Wainwright has adjusted the price target for Enliven (ELVN, Financial), lifting it from $39 to $40. The firm maintains its Buy rating on the company's shares following the release of its first-quarter financial results. This move reflects a positive outlook on Enliven's market performance and potential growth.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Enliven Therapeutics Inc (ELVN, Financial) is $38.14 with a high estimate of $42.00 and a low estimate of $33.00. The average target implies an upside of 91.77% from the current price of $19.89. More detailed estimate data can be found on the Enliven Therapeutics Inc (ELVN) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Enliven Therapeutics Inc's (ELVN, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
